Efficacy and Safety of TAK-875 in Combination With Sitagliptin in Participants With Type 2 Diabetes Mellitus
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 368 participants.
Also called NCT01414920
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 368 participants
- Sponsor
- Registry
-
NCT01414920 -
U1111-1115-5044
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT01414920. Randomized; quadruple masking; primary purpose treatment. Start 2011-08 (registry gives no type); primary completion 2012-08 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of TAK-875 in Combination With Sitagliptin in Participants With Type 2 Diabetes Mellitus
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- TAK-875
- Intervention (Drug)
- TAK-875
- Intervention (Drug)
- Sitagliptin
- Intervention (Drug)
- TAK-875 and Sitagliptin
- Intervention (Drug)
- TAK-875 and Sitagliptin
- Lead sponsor
- Takeda
Record details
- Record id
cardio:ct-nct01414920- Content hash
432828fd4916558dd8f0818d38afead1fdad635d8b5a288c3c459519ed4acf6b